What Is KPV?
KPV (H-Lys-Pro-Val-OH) is a synthetic tripeptide corresponding to residues 11-13 of α-melanocyte-stimulating hormone (α-MSH). α-MSH is a 13-residue peptide derived from POMC (pro-opiomelanocortin) by post-translational processing. Its C-terminal tripeptide sequence —KPV — was identified in the 1980s as the minimal fragment capable of replicating α-MSH's anti-inflammatory and antipyretic actions.
The remarkable finding that three amino acids can replace a 13-residue peptide for specific anti-inflammatory endpoints reflects the modularity of melanocortin receptor pharmacology: the N-terminal His-Phe-Arg-Trp core drives melanogenic/endocrine effects, while the C-terminal KPV sequence is responsible for anti-inflammatory activity through a partially receptor-independent mechanism.
NF-κB Inhibition Mechanism
The primary anti-inflammatory mechanism of KPV involves inhibition of the NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) transcription factor pathway — the master regulator of inflammatory cytokine gene expression:
KPV inhibits IKK (IκB kinase) complex activation, preventing IκB phosphorylation and degradation — the critical step gating NF-κB nuclear entry
Reduced p65/p50 translocation to nucleus → ↓ transcription of IL-1β, IL-6, IL-8, TNF-α, COX-2, iNOS
KPV reduces NLRP3 inflammasome assembly and caspase-1 activation → ↓ IL-1β and IL-18 maturation and secretion
Attenuates p38-MAPK and JNK phosphorylation downstream of inflammatory stimuli, reducing AP-1-driven cytokine production
Importantly, KPV can enter cells directly — its small size (3 AA, 328 Da) allows passive diffusion or active transport into intracellular compartments. This enables KPV to inhibit NF-κB activity intracellularly, not only via surface receptor activation. This intracellular mechanism may explain effects that persist even in MC receptor-negative cell types.
Gut Inflammation & IBD Research
KPV's most well-studied research application is in intestinal inflammation models, particularly those replicating inflammatory bowel disease (IBD):
DSS Colitis (Murine Model)
The dextran sodium sulphate (DSS) colitis model is the most widely used preclinical IBD model. In DSS-colitis studies:
- KPV (10–50 µg/kg IP or oral) significantly reduced DAI (disease activity index) scores, including body weight loss, rectal bleeding, and stool consistency
- Histological scoring: reduced epithelial ulceration, inflammatory cell infiltrate, crypt destruction vs vehicle controls
- Mucosal cytokines: ↓ IL-1β, IL-6, TNF-α, IFN-γ; ↑ anti-inflammatory IL-10 ratio
- Myeloperoxidase (MPO) activity — a marker of neutrophil infiltration — significantly reduced in colon tissue
TNBS Colitis (Crohn's Disease Model)
The trinitrobenzene sulphonic acid (TNBS) model replicates transmural Th1-driven colitis resembling Crohn's disease. KPV demonstrated similar efficacy — reduced weight loss, histological score, and colon TNF-α/IFN-γ levels — with activity comparable to prednisolone at equimolar doses in some experimental protocols.
KPV's small size and stability allow oral bioavailability studies that larger peptides cannot achieve. Research by Laroui et al. (2014, Gastroenterology) demonstrated KPV-loaded nanoparticles delivered orally to DSS-colitis mice localised to inflamed colonic tissue and produced anti-inflammatory effects — a proof-of-concept for targeted oral peptide delivery for IBD.
Mucosal Healing Research
Beyond suppressing acute inflammation, KPV promotes active mucosal healing — the restoration of gut epithelial barrier integrity after inflammatory damage:
- Tight junction restoration: KPV upregulates occludin, claudin-1, and ZO-1 expression in intestinal epithelial cells damaged by LPS or cytokine challenge, restoring transepithelial electrical resistance (TEER) in Caco-2/T84 monolayer models
- Epithelial migration: KPV promotes intestinal epithelial cell migration (wound scratch assay) — a prerequisite for mucosal re-epithelialisation after ulceration
- Goblet cell restoration: Chronic inflammation depletes mucus-producing goblet cells; KPV has been shown to partially preserve goblet cell number in colitis models
- Angiogenesis: Promotes VEGF-A expression in intestinal myofibroblasts, facilitating vascular repair in ulcerated mucosa
Systemic Anti-Inflammatory Research
KPV's NF-κB inhibitory properties extend beyond the gut to systemic inflammatory conditions:
Arthritis Models
In collagen-induced arthritis (CIA) and adjuvant arthritis rodent models, KPV reduced joint swelling, histological synovitis scores, and serum inflammatory markers (IL-6, CRP). The effect was additive with low-dose methotrexate in one experimental design.
Wound Healing
KPV accelerates wound closure in rodent excision models by reducing excessive inflammatory phase duration and promoting proliferative phase entry. Full-thickness wound closure time was reduced 20–30% in KPV-treated groups vs controls.
Neuroinflammation
Limited data from hippocampal astrocyte culture models suggests KPV reduces LPS-induced NF-κB activation and IL-1β production in glial cells — expanding potential research applications to neuroinflammatory models.
KPV vs Full α-MSH
| Property | α-MSH (1-13) | KPV (11-13) |
|---|---|---|
| Length | 13 AA | 3 AA |
| MW | ~1665 Da | 328 Da |
| MC1R melanogenesis | Strong | None |
| MC4R sexual/CNS effects | Moderate | None |
| NF-κB anti-inflammatory | ✓ Strong | ✓ Strong (equivalent) |
| NLRP3 suppression | ✓ | ✓ |
| Cytokine ↓ (IL-6, TNF-α) | ✓ | ✓ |
| Oral bioavailability potential | Low (13 AA) | Higher (3 AA) |
| Intracellular penetration | Limited | Better (small size) |
For gut and systemic anti-inflammatory research where melanogenic or pituitary effects would confound results, KPV is the preferred research tool over full α-MSH. Its smaller size also enables formulation strategies (nanoparticles, hydrogels) that are impractical for larger peptides.
Research Protocols
DSS Colitis (Standard)
- Species: C57BL/6 mice (males, 8–10 weeks)
- DSS induction: 2.5–3% DSS in drinking water × 7 days
- KPV dose: 10–50 µg/kg IP or oral (nanoparticle formulation)
- Endpoints: DAI (daily), colon length, MPO, H&E histology, cytokine ELISA
Epithelial Barrier (In Vitro)
- Cell line: Caco-2 or T84 monolayers (21-day differentiation)
- Damage: IL-1β + TNF-α (10 ng/mL each) × 24h
- KPV treatment: 0.1–100 nM co-treatment
- Endpoints: TEER (Ω·cm²), FITC-dextran permeability, TJ protein Western
NF-κB Reporter Assay
- Cell: RAW264.7 macrophages with NF-κB-luciferase reporter
- Stimulus: LPS (100 ng/mL) ± KPV (1–1000 nM)
- Readout: Luciferase RLU at 6h post-stimulation
- Controls: IKK inhibitor (positive), vehicle (negative)
FAQ
What is KPV?
The C-terminal tripeptide (Lys-Pro-Val) of α-MSH. It retains the anti-inflammatory properties of α-MSH — NF-κB inhibition, cytokine suppression, NLRP3 inflammasome suppression — without melanogenic or pituitary hormone effects.
How does KPV reduce gut inflammation?
KPV inhibits NF-κB signalling in intestinal epithelial cells and immune cells, reducing IL-1β, IL-6, TNF-α production. It also suppresses NLRP3 inflammasome and promotes tight junction restoration for barrier repair.
Why is KPV preferred over full α-MSH for gut research?
KPV lacks the melanogenic (MC1R) and endocrine (MC4R, MC5R) effects of α-MSH, providing cleaner anti-inflammatory data without confounding pigmentation or hormonal changes. Its smaller size also enables oral delivery formulations impractical for larger peptides.
Can KPV be taken orally?
In research models, KPV has been studied via oral routes, particularly as nanoparticle-encapsulated formulations that protect it from GI proteolysis and deliver it to colonic tissue. This is a research finding — not a clinical recommendation. Raw oral KPV is subject to proteolytic degradation in the GI tract.
KPV for Research
Lyophilised KPV ≥98% purity (HPLC), H-Lys-Pro-Val-OH free form, with full COA and mass spec verification.
View KPV →